Glenmark Life Sciences
Glenmark Life Sciences Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Glenmark Life Sciences
Start SIPGlenmark Life Sciences Investment Rating
-
Master Rating:
-
Glenmark Life Sciences has an operating revenue of Rs. 2,053.96 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 27% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 19 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 140 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 541 | 509 | 490 | 514 |
| Operating Expenses Qtr Cr | 395 | 366 | 343 | 372 |
| Operating Profit Qtr Cr | 145 | 144 | 147 | 142 |
| Depreciation Qtr Cr | 11 | 10 | 10 | 10 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 36 | 37 | 38 | 39 |
| Net Profit Qtr Cr | 105 | 107 | 109 | 99 |
Glenmark Life Sciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 396.55
- 50 Day
- 408.82
- 100 Day
- 418.95
- 200 Day
- 449.95
- 20 Day
- 400.77
- 50 Day
- 415.54
- 100 Day
- 414.4
- 200 Day
- 432.82
Glenmark Life Sciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 382.6 |
| Second Resistance | 385.6 |
| Third Resistance | 388 |
| RSI | 19.43 |
| MFI | 12.8 |
| MACD Single Line | -8.31 |
| MACD | -10.52 |
| Support | |
|---|---|
| First Resistance | 377.2 |
| Second Resistance | 374.8 |
| Third Resistance | 371.8 |
Glenmark Life Sciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 78,652 | 5,573,281 | 70.86 |
| Week | 67,218 | 4,721,406 | 70.24 |
| 1 Month | 51,207 | 3,531,241 | 68.96 |
| 6 Month | 118,364 | 7,878,279 | 66.56 |
Glenmark Life Sciences Result Highlights
Glenmark Life Sciences Synopsis
NSE-Medical-Ethical Drugs
Glenmark Life Scienc belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 2123.21 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2022. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.| Market Cap | 4,611 |
| Sales | 2,054 |
| Shares in Float | 2.08 |
| No of funds | 23 |
| Yield | 2.79 |
| Book Value | 2.24 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | |
| Alpha | -0.15 |
| Beta | 0.57 |
Glenmark Life Sciences
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 82.85% | 82.85% | 82.85% | |
| Mutual Funds | 0.71% | 0.71% | ||
| Insurance Companies | 0.07% | 0.07% | ||
| Foreign Portfolio Investors | 4.45% | 6.04% | 7.58% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 9.78% | 9.14% | 8.14% | |
| Others | 2.85% | 1.19% | 0.72% |
Glenmark Life Sciences Management
| Name | Designation |
|---|---|
| Mr. Glenn Saldanha | Chairman & Non-Exe.Director |
| Mr. Yasir Rawjee | Managing Director & CEO |
| Mr. Sumantra Mitra | Executive Director |
| Mr. V S Mani | Non Executive Director |
| Mr. Sridhar Gorthi | Independent Director |
| Mrs. Manju Agarwal | Independent Director |
| Mr. Taruvai Laxminarayanan Easwar | Independent Director |
| Ms. Gita Nayyar | Independent Director |
Glenmark Life Sciences Forecast
Price Estimates
Glenmark Life Sciences Corporate Action
Glenmark Life Sciences FAQs
What is Share Price of Glenmark Life Sciences ?
Glenmark Life Sciences share price is ₹376 As on 04 February, 2023 | 07:43
What is the Market Cap of Glenmark Life Sciences ?
The Market Cap of Glenmark Life Sciences is ₹4610.7 Cr As on 04 February, 2023 | 07:43
What is the P/E ratio of Glenmark Life Sciences ?
The P/E ratio of Glenmark Life Sciences is 11 As on 04 February, 2023 | 07:43
What is the PB ratio of Glenmark Life Sciences ?
The PB ratio of Glenmark Life Sciences is 2.2 As on 04 February, 2023 | 07:43